JPRN-UMIN000051776
Completed
未知
A Retrospective Study to Explore Early Screening Indicators for AD pathology - A Retrospective Study to Explore Early Screening Indicators for AD pathology
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Mild Cognitive impairment Healthy adult volunteers
- Sponsor
- Oita University
- Enrollment
- 200
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Subjects of this study are participants in Usuki Cohort (the cohort of local elderly residents in Usuki City, Oita Prefecture) and those who visited Oita University Hospital, and they meet all the following inclusion criteria. 1\. Subjects with some missing data. 2\. Subjects who have stated their willingness to participate in the research. 3\. Any other subjects who are judged to be ineligible by the principal investigator or sub\-investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
Development of an early screening instrument for Autism Spectrum Disorder.Health Condition 1: F840- Autistic disorderCTRI/2022/04/041686C A Ashitha Sreelakshmi
Completed
Not Applicable
To study early treatment response in peripheral blood on Day 15 in B cell Acute Lymphoblastic Leukemia patientsHealth Condition 1: null- B cell Acute Lymphoblastic LeukemiaCTRI/2016/08/007180Tata Memorial Hospital100
Not yet recruiting
Not Applicable
The effect of graduated return to high-intensity exercise on time to return to play in the context of sports-related concussions.Sports-related concussionMild Traumatic Brain InjuryACTRN12618000485235Dr Hamish Osborne50
Recruiting
Not Applicable
Exploratory study for the usefulness of early introduction of anifrolumab in the first remission induction therapy for systemic lupus erythematosussystemic lupus erythematosusJPRN-jRCTs031230358Tsuboi Hiroto10
Completed
Not Applicable
A Retrospective Study to Evaluate the Early Real-world Evidence of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) in IndiaNeurovascular Age-related Macular DegenerationNCT05834075Novartis Pharmaceuticals63